adafosbuvir

Adafosbuvir (AL-335) is an orally bioavailable, uridine-based nucleotide analog prodrug developed by Alios BioPharma, a subsidiary of Johnson & Johnson, for the treatment of chronic hepatitis C virus (HCV) infection. It functions as a pangenotypic inhibitor of the HCV NS5B RNA-dependent RNA polymerase. Upon administration, adafosbuvir is rapidly absorbed and metabolized into its active triphosphate form, which acts as a chain terminator by competing with natural nucleotides for incorporation into the nascent viral RNA strand. The drug was evaluated in Phase 1 and Phase 2 clinical trials, both as a monotherapy and as a component of the triple-combination regimen JNJ-4178 (alongside odalasvir and simeprevir). However, in September 2017, Johnson & Johnson announced the discontinuation of its hepatitis C development program, including adafosbuvir, due to a strategic shift in its infectious disease portfolio.

Other names

GS-7977GS7977GS 7977PSI-7977PSI7977PSI 7977